Cofrogliptin study for LADA patients
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether an oral medication called Cofrogliptin can help your pancreas make more insulin. It's for adults with LADA who still produce some of their own insulin and do not need daily insulin right away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have been diagnosed with LADA (a slow-progressing form of diabetes that starts in adulthood).
- At least 6 months passed after your diagnosis before you needed daily insulin.
- A blood test shows your body still makes some insulin (C-peptide level of at least 200 pmol/L).
- Your average blood sugar over 2–3 months (A1C) is 9.0% or lower.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a hybrid closed-loop insulin pump system for people with LADA (a slow-progressing form of autoimmune diabetes). It aims to see if the system can improve blood sugar control and reduce hypoglycemia.
This study tests whether berberine (a supplement-like medicine) plus inulin (a fiber) can improve blood sugar control in people with LADA, a type of autoimmune diabetes. It may help lower HbA1c (a measure of average blood sugar) and improve diabetes care.
This trial tests if adding either cofrogliptin or linagliptin (two pills that help control blood sugar) to your current insulin treatment can improve diabetes control. It is for adults with type 2 diabetes whose blood sugar is still not well managed with insulin and certain other diabetes pills.
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
This trial tests a new pill called cofrogliptin against a standard medicine called acarbose to see which better controls blood sugar in people with type 2 diabetes who have never taken diabetes medication. It's for those managing their diabetes with diet and exercise alone.
This study tests a new once-every-2-weeks pill (cofrogliptin) added to your current diabetes medications (metformin and dapagliflozin) compared to a daily pill (linagliptin). It may help improve blood sugar control with fewer daily pills.
Hear when a new Latent Autoimmune Diabetes in Adults (LADA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.